ジェノタイピングの世界市場：現状分析と予測（2021年～2027年）

世界のジェノタイピングの市場規模は、予測期間（2021年～2027年）中に約20％のCAGRで成長すると予測されています。

希少疾患のジェノタイピングは、未診断疾患の原因を特定するのに役立ち、何年も通院したり、不必要な検査を受けたりするのを防ぐことができることから、市場の成長を後押ししています。さらに、癌などの疾患の有病率が増加していることも、ジェノタイピング診断の需要を高めています。

当レポートでは、世界のジェノタイピング市場について調査しており、市場の洞察、市場の動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場のイントロダクション

• 市場の定義
• 制限
• ステークホルダー
• レポートで使用される通貨

第2章 調査方法または仮定

• ジェノタイピング市場の調査プロセス
• ジェノタイピング市場の調査手法
• 予測方法
• 回答者のプロファイル
• ジェノタイピング市場調査の主な目的

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 世界のジェノタイピング市場におけるCOVID-19の影響

第6章 世界のジェノタイピング市場の収益（2019年～2027年）

第7章 市場の洞察：製品/サービスタイプ別

• 試薬とキット
• ジェノタイピングサービス
• 装置
• バイオインフォマティクス

第8章 市場の洞察：技術別

• PCR
• シーケンス
• 電気泳動
• マイクロアレイ
• その他

第9章 市場の洞察：エンドユーザー別

• 製薬およびバイオテクノロジー企業
• 病院および診療所
• 学術および政府機関
• 診断および研究機関
• その他

第10章 市場の洞察：地域別

• 北米のジェノタイピング市場
  • 米国
  • カナダ
  • その他の北米
• 欧州のジェノタイピング市場
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋のジェノタイピング市場
  • 中国
  • 日本
  • インド
  • オーストラリア
  • その他のアジア太平洋
• その他

第11章 ジェノタイピング市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第12章 ジェノタイピング市場の機会

第13章 ジェノタイピング市場の動向

第14章 法規制の枠組み

第15章 需要と供給側分析

• 需要側分析
• 供給側分析

第16章 バリューチェーン分析

第17章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第18章 会社概要

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Qiagen Inc.
• F. Hoffmann-La Roche Ltd.
• Fluidigm Corporation
• Danaher Corporation
• Agilent Technologies
• Eurofins Scientific Inc.
• GE Healthcare Inc.
• Bio-Rad Laboratories Inc.

第19章 免責事項

Global Genotyping Market is anticipated to grow with an elevated CAGR of around 20% over the forecast period (2021-2027). Genotyping is the process of determining the DNA sequence, called a genotype, at specific positions within the genome of an individual. Sequence variations can be used as markers in linkage and association studies to determine genes relevant to specific traits or diseases.

The genotyping of rare disease help doctors pinpoint the cause of undiagnosed disorders, helping families avoid years of hospital visits and unnecessary tests. These factors are anticipated to boost the market. Furthermore, the increasing prevalence of diseases like cancer along with the surging incidences of rare diseases rises the demand for genotyping diagnostics. According to the ministry of health and welfare of the family, it is estimated that globally around 6000 to 8000 rare diseases exist with new rare diseases being reported in the medical literature regularly. The increasing interest of the global players and the institutions along with the continuous growth of the biotechnology industry also drives the market for genotyping. For instance, As per Invest India, In 2020, the Biotech industry reached a market size of $ 70.2 Bn, rising 12.3% from the previous year. The bioeconomy has observed almost a 95% increase in valuation over the period of five years.

llumina Inc., Thermo Fisher Scientific Inc., Qiagen Inc., F. Hoffmann-La Roche Ltd., Fluidigm Corporation, Danaher Corporation, Agilent Technologies, Eurofins Scientific Inc., GE Healthcare Inc., and Bio-Rad Laboratories Inc, are some of the prominent players operating in the Genotyping market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with new varieties of Genotyping devices.

Insights Presented in the Report

"Amongst Product/Services, Reagents & Kits segment holds the major share"

Based on product/services, the market is fragmented into Reagents & Kits, Genotyping Services, Instruments, and Bioinformatics. The Reagents & Kits segment accounted for a significant market share in 2020 this is mainly due to the increasing investments in R&D and increasing demand for genetic testing drives the market for genotyping industry. However, the bioinformatic segment is expected to witness lucrative growth in the genotyping market owing to the increasing demand for software and the better databases require to store the genetic information. Furthermore, the integration of the devices with the internet and the public network also drives the segmental growth during the forecast period.

"Amongst Technology, sequencing segment is expected to hold the major share"

Based on technology, the market is segmented into PCR, sequencing, electrophoresis, microarray, and others. The PCR segment grabbed a significant market share in 2020. The continuously rising number of incidences of genetic disorders and the deaths raise the growth of the PCR. During the forecast, the sequencing segment is expected to have a considerable market share. This is mainly due to the technological advancement in sequencing technology and frequent product launches by the companies. For instance, in January 2021, Stanford Launched Clinical Whole-Genome Sequencing for Inherited Cardiovascular Testing.

"Amongst end-users, diagnostic & research segment expected to hold the major share"

Based on end-users, the market is fragmented into pharmaceutical & biotechnology companies, hospitals and clinics, academic & government institutes, diagnostic & research institutions, and others. The pharmaceutical & biotechnology companies held a significant market share in 2020. Genomics is enabling pharmaceutical companies to take a more personalized approach to drug development and is expected to result in safer and more effective drugs. However, the diagnostic & research institution segment is predicted to have a significant share in genotyping market in the future. This is mainly due to increasing investment in R&D worldwide along with an increasing number of cases of genetic disorders. For instance, as per UNESCO, Global spending on R&D has reached a record high of almost US$ 1.7 trillion. About 10 countries account for 80% of spending.

"North America represents one of the largest markets of Genotyping market"

For a better understanding of the market dynamics of the Genotyping market, a detailed analysis was conducted for different regions across the globe including North America (U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. In 2020, North America dominated the Genotyping industry. This can be mainly due to the presence of well-established market players and frequent product launches along with the presence of government-funded organizations in the region. For instance, The National Human Genome Research Institute (NHGRI) is a part of the National Institutes of Health (NIH) are government organization supported and funded by the U.S government that has a record of the human genome and the genetic disorder.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts

• The report presents a quick review of overall industry performance at one glance

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

• The study comprehensively covers the market across different segments

• Deep dive regional level analysis of the industry

Customization Options:

The global genotyping market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Genotyping Market
• 2.2. Research Methodology of the Genotyping Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Genotyping Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL GENOTYPING MARKET COVID-19 IMPACT

6 GLOBAL GENOTYPING MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY PRODUCT/SERVICE TYPE

• 7.1. Reagents & Kits
• 7.2. Genotyping Services
• 7.3. Instruments
• 7.4. Bioinformatics

8 MARKET INSIGHTS BY TECHNOLOGY

• 8.1. PCR
• 8.2. Sequencing
• 8.3. Electrophoresis
• 8.4. Microarray
• 8.5. Others

9 MARKET INSIGHTS BY END-USERS

• 9.1. Pharmaceutical & Biotechnology companies
• 9.2. Hospitals and clinics
• 9.3. Academic & government institutes
• 9.4. Diagnostic & research institutions
• 9.5. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America Genotyping Market
  • 10.1.1. United States
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe Genotyping Market
  • 10.2.1. Germany
  • 10.2.2. France
  • 10.2.3. U.K.
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia Pacific Genotyping Market
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. Rest of Asia Pacific
• 10.4. Rest of World Genotyping Market

11 GENOTYPING MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 GENOTYPING MARKET OPPORTUNITIES

13 GENOTYPING MARKET TRENDS

14 LEGAL & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. Illumina Inc.
• 18.2. Thermo Fisher Scientific Inc.
• 18.3. Qiagen Inc.
• 18.4. F. Hoffmann-La Roche Ltd.
• 18.5. Fluidigm Corporation
• 18.6. Danaher Corporation
• 18.7. Agilent Technologies
• 18.8. Eurofins Scientific Inc.
• 18.9. GE Healthcare Inc.
• 18.10. Bio-Rad Laboratories Inc.

19 DISCLAIMER